First episode psychosis and weight gain a longitudinal perspective in Cheshire UK: a comparison between individuals with nonaffective versus affective psychosis.
BMI
affective psychosis
nonaffective psychosis
weight gain
Journal
Cardiovascular endocrinology & metabolism
ISSN: 2574-0954
Titre abrégé: Cardiovasc Endocrinol Metab
Pays: United States
ID NLM: 101730894
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
24
03
2023
accepted:
26
05
2023
medline:
26
6
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
Early weight gain following initiation of antipsychotic treatment predicts longer-term weight gain, with attendant long-term consequences including premature cardiovascular events/death. An important question is whether there is a difference in weight change over time between people with affective versus nonaffective psychosis. Here we describe the results of a real-world analysis of the BMI change in the months postdiagnosis with affective versus nonaffective psychosis. We undertook an anonymised search across one Primary Care Network in Cheshire, UK with a total population of 32 301 individuals. We reviewed the health records of anyone who had been diagnosed over a 10-year period between June 2012 and June 2022 for the first time with first episode nonaffective psychosis versus psychosis associated with depression or bipolar affective disorder (affective psychosis). The overall % change in BMI was +8% in nonaffective psychosis individuals and +4% in those with a diagnosis of affective psychosis - however, the distribution was markedly skewed for nonaffective psychosis patients. Using caseness as >30% increase in BMI; affective = 4% cases and nonaffective = 13% cases, there was a three-fold difference in terms of increase in BMI. In regression analysis, the The differences observed here in the distribution of weight change over time between individuals with affective versus nonaffective psychosis may relate to underlying constitutional differences. The phenotypic and genetic factors underlying this difference remain to be defined.
Identifiants
pubmed: 37361477
doi: 10.1097/XCE.0000000000000286
pmc: PMC10289689
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0286Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Lancet Psychiatry. 2019 Aug;6(8):675-712
pubmed: 31324560
BMC Psychiatry. 2020 Nov 7;20(1):528
pubmed: 33160310
Int J Neuropsychopharmacol. 2013 Jul;16(6):1205-18
pubmed: 23199972
Clin Proteomics. 2020 Oct 27;17:38
pubmed: 33117088
Can J Psychiatry. 2014 Feb;59(2):76-88
pubmed: 24881126
Am J Psychiatry. 1999 Nov;156(11):1686-96
pubmed: 10553730
JAMA Psychiatry. 2014 Dec 1;71(12):1350-63
pubmed: 25321337
Expert Opin Drug Saf. 2020 Mar;19(3):295-314
pubmed: 31952459
Eur Psychiatry. 2014 Sep;29(7):402-7
pubmed: 24439513
Sci Rep. 2017 Nov 7;7(1):14738
pubmed: 29116126
Hum Psychopharmacol. 2017 Mar;32(2):
pubmed: 28370308
Front Neurosci. 2015 Sep 03;9:297
pubmed: 26388714
Lancet Psychiatry. 2020 Jan;7(1):64-77
pubmed: 31860457
J Psychopharmacol. 2016 Aug;30(8):717-48
pubmed: 27147592
Aust N Z J Psychiatry. 2017 Jan;51(1):75-82
pubmed: 26769981